Viewing Study NCT02082899



Ignite Creation Date: 2024-05-06 @ 2:38 AM
Last Modification Date: 2024-10-26 @ 11:21 AM
Study NCT ID: NCT02082899
Status: COMPLETED
Last Update Posted: 2014-07-11
First Post: 2014-03-04

Brief Title: A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis EBI-005-AC-1
Sponsor: Eleven Biotherapeutics
Organization: Eleven Biotherapeutics

Study Overview

Official Title: A Single Center Randomized Double-Masked Vehicle-Controlled Parallel Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber EEC Model and Conjunctival Allergen Provocation Test CAPT Model
Status: COMPLETED
Status Verified Date: 2014-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a Phase II Single Center Randomized Double-Masked Vehicle-Controlled Parallel Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber EEC Model and Conjunctival Allergen Provocation Test CAPT Model Approximately 150 subjects will be enrolled and randomized in one study center in Canada for a duration of 033 years
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None